Mang Yu, Ph.D.

Dr. Yu is the President and CEO, NexBio, Inc., San Diego. NexBio focuses on the development of novel, broad-spectrum prophylaxis and therapeutics for the prevention and treatment of life threatening human respiratory infectious diseases.

Prior to founding NexBio, Dr. Yu was a co-founder & Executive Vice President of Perlan Therapeutics, a biopharmaceutical company focusing on the development of treatments for the common cold. While at Perlan, Dr. Yu successfully raised multiple rounds of venture capital that supported the company development of ColdSol(TM) for the prevention and treatment of the common cold caused by human rhinovirus. Under his leadership, ColdSol(TM) won the Most Innovative New Product (MIP) Award in 2002. Prior to Perlan, Dr. Yu co-founded Immusol, Inc. where he served as Director of HIV Gene Therapy, and later as Director of Target Discovery & Gene Therapy (for HIV, HBV, & HCV). While at Immusol, Dr. Yu was responsible for a corporate partnership with Pfizer on an anti-HIV drug, MY-2. Before his immigration to US in 1985, Dr. Yu was an Assistant Professor at the Shanghai Medical University. He is an annual guest speaker on bio- entrepreneurship for an MBA class at San Diego State University. Dr. Yu holds a Ph.D. degree in Biochemistry & Molecular Biology from Indiana University, School of Medicine, and completed his post-doctoral training at University of California, San Diego.